|
|
|
Royal Pharmaceutical Society of Great Britain, AAPS and APS, Royal Pharmaceutical Society of Great Britain, 1 Lambeth High St, London
31/3/2008 - 2/4/2008
PROGRAMME MONDAY 31 MARCH SESSION 1: The drivers for change Moderators: Richard Storey, AstraZeneca, UK and Rob Price, University of Bath, UK What are the shortfalls of the current approaches to powder technology? Fernando Muzzio, Rutgers University, USA The current manufacturing environment Neil Wilkinson, AstraZeneca, UK Pharmaceutical powders: A journey from understanding to control to design Chris Sinko, Pfi zer, USA Continuous processes and life cycle management - the factory of the future Jim Fox, GlaxoSmithKline, UK Creating a regulatory environment to encourage innovation and change Janet Woodcock, FDA, USA Lunch SESSION 2: Engineering and control of particle formation 1 Moderator: Alastair Florence, University of Strathclyde, UK Nucleation simulation: what do we know about nucleation on the molecular scale? Angelo Gavezzotti, University of Milan, Italy Crystallisation engineering to aid drug product processing or performance Amy Gillon, AstraZeneca, UK Control of polymorphic systems during crystallization Roger Davey, University of Manchester, UK The use of ultrasonic crystallisation in providing a level of control in crystallisation procedures Graham Ruecroft, Prosonix, UK Round table discussion Wine Reception TUESDAY 1 APRIL SESSION 2: (continued) Engineering and control of particle formation 2 Moderators: Rob Price, University of Bath, UK and Claire Madden, Molecular Profi les, UK Particle formation and technologies, Particle size optimization Ken Morris, Purdue, USA Novel methodologies for the production of material for particulate systems Jeremy Clarke, Pfi zer, UK Surface interactions and their importance in performance of pharmaceutical formulations Rob Price, University of Bath, UK Investigations into the variation of physical properties of excipients Sarah Dilworth, AstraZeneca, UK Investigating powder processing David Morton, Victorian College of Pharmacy, Monash University, Australia Lunch SESSION 3: Opportunities for optimizing particulate properties using crystal modifi cations Moderator: Bill Jones, University of Cambridge, UK The salt-cocrystal continuum Scott Childs, Aptuit, USA The use of solvates and hydrates as pharmaceutical forms Gerard Coquerel, University of Rouen, France The issue of cocrystal formation by grinding and the possible role of amorphous intermediates Marc Descamps, University of Lille, France Obtaining cocrystals and using synthons in the design of cocrystals Roland Boese, University of Duisburg-Essen, Germany Crystal structure prediction, an introduction and the potential for predicting cocrystals Aurora Cruz Cabeza, University of Cambridge, UK Round table discussion Social programme with dinner WEDNESDAY 2 APRIL SESSION 4 Control of processes for particulate-based systems Richard Storey, AstraZeneca, UK and David Morton, Victorian College of Pharmacy, Monash University, Australia Aspects of control in the formulation of particulate products Jonathan Seville, University of Birmingham, UK Characterization of materials for formulation control - oral & inhaled Martyn Ticehurst, Pfi zer, UK Use of Design of Experiments in identifying design space TBA Understanding particle surfaces/conditioning Lars-Erik Briggner, AstraZeneca, Sweden Understanding processes using PAT, case studies Gavin Reynolds, AstraZeneca, UK The criticality of sampling and relevance of measurement in process control Dave Rudd, GlaxoSmithKline, UK Lunch SESSION 5: The intellectual property, regulatory and educational success factors for facilitating this paradigm shift Tom Sam, Organon, Netherlands and Ken Leiper, Benson Associates, UK The intellectual property challenges arising from enhanced knowledge of powders, processability and isolation TBA A regulatory perspective of the related challenges for industry, agencies, pharmacopoeias and the qualifi ed person Gordon Munro, Watson Pharmaceuticals, USA The adoption of new technologies requires new skills – how will the global challenge be facilitated? Fernando Muzzio, Rutgers University, USA Close of conference
|
|
|
|
|
|
Organized by:
|
|
Royal Pharmaceutical Society of Great Britain |
|
Invited Speakers:
|
|
LEARN FROM A TEAM OF EXPERTS Programme Committee Conference chairs: Richard Storey (Associate Principle Scientist, AstraZeneca, UK) and Rob Price (Reader in Pharmaceutical Technology, University of Bath, UK) Alastair Florence (University of Strathclyde, UK), Ken Leiper (Benson Associates, UK), Claire Madden- Smith (Molecular Profi les, UK), David Morton (Victorian College of Pharmacy, Monash University, Australia), Bill Jones (University of Cambridge, UK), Tom Sam (Organon, Netherlands)
|
|
|
|
|
|
Deadline for Abstracts:
|
|
ASAP
|
|
|
|
|
|
Registration:
|
|
DELEGATE FEES Delegate fees are £950 for members of RPSGB, APS or AAPS or £995 for non-members. Fees are inclusive of lunches and refreshments, a full social programme (including dinner on the last evening) and comprehensive course documentation. REGISTER BEFORE 30 NOVEMBER 2007 FOR THE EARLY BIRD FEE OF £895
|
|
E-mail:
|
|
science@rpsgb.org
|
|
|
|
|
|
|
|